Topic Listing for Progenics Pharmaceuticals

Access University Information Accounts Payable Accrued Expenses
Accounts Receivable Accrued Rights
Adarc Additional Formulations
Additional Representation Warranty Ono Additional Representations Warranties Progenics
Additional Rights Adjustments
Administration Affiliate
Aggregated Option Exercises Last End Values Agreement
Alphavax Human Vaccines Alton Kremer Phd
Amendment Amendments
Amendments Articles Incorporation Bylaws Changes Amgen Fremont Inc
Amgen Fremont Inc Formerly Abgenix Ann Marie Assumma
Ann Marie Assumma Vice President Regulatory Affairs Annual Bonus
Anti-takeover Provisions Make Removal Board Directors Management Difficult Antigenics Inc
Application Patent Term Extension Aquila Biopharmaceuticals
Assignment Assignment Trademarks
Assignment Transfer Beneficiaries Audit Committee
Audits Available Information
Available Shares Award Agreement
Awards Baker
Baker Executive Vice President 8211 Corporate Base Salary
Benedict Osorio Mba Benedict Osorio Mba Senior Vice President Quality
Beneficial Ownership Reporting Compliance Bla
Board Committee Meetings Board Directors Deems Approval 2005 Stock Incentive Plan
Calendar Cash Equivalents
Certain Transactions Certification Pursuant Rule 13a-14 15d-14 Securities Exchange Act
Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act Change Accounting Policy- Revenue Recognition
Change Control Change-in-control
Changes Internal Control Over Financial Reporting Charles Baker
Claim Clinical Trial Expenses
Clinical Trials Clinical Trials Take Longer Expect
Code Business Ethics Conduct Collaboration
Collaboration Between Wyeth Pharmaceuticals Progenics Collaborative Marketing Development Agreements
Collaborator Collegeville Tarrytown 2008
Collegeville Tarrytown 2008 8211 Columbia University
Combination Product Commercial Sale
Commercialization Commercialization Milestone Payments
Commercially Reasonable Efforts Commitments Contingencies
Committee Authority Committee Members
Comparative Stock Performance Graph Compensation Committee
Compensation Directors Competitors Developing Opioid Antagonist Reach Market Ahead Adversely
Compliance Compound
Comprehensive Loss Condensed Balance Sheets
Confidential Information Confidentiality
Consent Independent Registered Public Accounting Firm Consent Progenics-ono Agreement
Contractors Control Controlled
Controlling Affiliate Controls Procedures
Cooperation Cooperation Sharing Information
Coordination Corporate Debt Securities
Cost Recalls Costs Assistance
Counterparts Critical Accounting Policies
Cumulative Royalties Currency
Dalton Date Report Earliest Event Reported 2004
David Scheinberg Phd Decision Making
Deferrals Payment Definition Change Control
Definitions Delegation Authority
Departure Directors Principal Officers Election Appointment Dependent Parties Variety Functions Arrangements Not Provide Benefits
Dependent Patents Other Intellectual Property Rights Validity Enforceability Description
Description Compensation Arrangement Respect Named Executive Officers Designation Participants
Desirable Qualities Skills Determination Awards
Development Development Activities
Development Milestone Payments Development Plan
Development Responsibilities Ono Developmental Research License
Disclosure Disclosure Notice
Dispute Resolution Disputes Cytogen Delay Halt Psma Programs
Documentation Technology Documents Incorporated Reference
Documents Information Drug Price Approval
Effect Change Control Effect Expiration
Effect Licenses Effect Termination Ono Cause
Effective Date Effective Date Amendment Termination
Efforts Election
Eligible Employees Employees
Employment Agreements Employment Service
Enforcement Ono Collaboration Patent Rights Enforcement Procedure
Enforcement Subject Patent Rights Entire Agreement
Entry Material Definitive Agreement Equity Compensation Plan Information
Esults Evaluation Candidates
Evaluation Disclosure Controls Procedures Even Obtain Marketing Approval Products They Might Not
Except Net Loss Per Share Except Par Value Share Amounts
Exceptions Exceptions Purchasing Securities Progenics
Excluded Molecules Exclusion
Executive Committee Exercise Price
Exercise Price Payment Exhibits
Expenses Exploitation Joint Patent Rights Know-how Other Provided Agreement
Exposed Product Liability Claims Future Not Able Obtain Extraordinary Notices
Facet Biotech Corporation Fair Value Measurements
Fda Fda Regulation
Field Financial Statements Exhibits
Financing Activities For-profit Companies Major Universities Research Institutions
Force Majeure Foreign Jurisdictions
Forfeiture Events Representations Form 10-k
Form 10-q Formation Jcc
Formation Purpose Freestanding Stock Appreciation Rights
Fte Rate Fully Paid-up Royalty Free License
Further Actions Further Assurances
Gaap General
General Claims General Provisions
Generic Product Generic Product Market Share
Gmp Governing Law
Grant Performance Awards Grant Restricted Stock Awards
Grant Stock Appreciation Rights Grant Stock Awards
Grant Stock Option Grant Stock Unit Awards
Grants Non-employee Directors Handle Hazardous Materials Comply Environmental Laws Regulations Expensive
Hcv Hcv Infection
Headings Health Care Reform Measures Enacted Operating Results Ability
History Operating Losses Never Profitable Hiv
Hiv Infection Aids Householding
Immediate Release Impact Recently Issued Accounting Standards
Implied Rights Incentives
Inconsistent Agreements Ind
Indebtedness Management Indemnification Ono
Indemnification Progenics Independent Contractors
Index Infringe Third-party Patent Other Intellectual Property Rights Need
Infringement Party Patents Course Action Initial Formulation
Interactions Regulatory Authority Territory Interim Financial Statements
Internal Process Identifying Candidates Interpretation
Intravenous Relistor Inventorship
Investigational New Drug Investing Activities
Involuntary Without Cause Termination Good Reason Israel
Itments Contingencies Japanese Regulatory Authority
Jcc Jdc
Joint Know-how Joint Patent Rights
Joint Technology Jsc
Jurisdiction Actions Related Intellectual Property Kmt Hepatech Inc
Know-how Know-how Disclosure Transfer
Kurt Briner Labs University Chicago
Lack Sales Marketing Experience Make Dependent Parties Expertise Law
Letterhead Officer Director Major Stockholder License Agreement
License Ono Progenics License Progenics Ono
License Wyeth Progenics Collaboration Patent Rights Know-how Wyeth8217s Licensed Activit Ies
Likely Need Additional Financing Access Capital Funding Uncertain Limited Manufacturing Capabilities Adversely Impact Ability Commercialize Products
Limited Transferability Nonqualified Stock Options Lose Key Management Scientific Personnel Depend Business Suffer
Marketable Securities Marketing Materials Corporate Branding
Marketplace Acceptance Depend Part Competition Industry Intense Mba
Meeting Agendas Meetings
Membership Membership Chairpersons
Methylnaltrexone Bromide Minimum Criteria Board Members
Mntx Montreal Quebec Tarrytown
Nda Net Loss
Net Loss Per Share Net Sales
New Delivery System Relistor Pre-filled Syringes Submitted European Nicole Williams Mba
Nitya Ray Phd Nominating Corporate Governance Committee
Nomination Directors Stockholders Non-assertion Ono
Non-assertion Rights Non-compete Non-disclosure Confidential Information Non-solicitation Agreements
Non-competition Non-exclusive License Ono Progenics
Non-exclusive License Progenics Ono Not Remedy Failure Achieve Milestones Satisfy Conditions Regarding
Not Yet Never Obtain Regulatory Approvals Need Market Notes Condensed Financial Statements
Notice Notice Annual Meeting Stockholders Held 2005
Notice Disclosure Off-balance Sheet Arrangements
Offering Pursuant Previously Filed 8220shelf8221 Registration Statement Oncology
Ono Ono Collaboration Know-how
Ono Collaboration Patent Rights Ono Collaboration Technology
Ono Independent Patent Rights Ono License Agreement
Ono Option Negotiate Ono Pharmaceutical
Ono8217s Affiliates Operating Activities
Opioids Oral Relistor
Ordinary Notices Other Awards
Other Business Other Compensation Benefit Plans
Other Compensation Considerations Other Current Assets
Other Events Other Income
Other Product Candidates Research Programs Other Regulation
Other Revenues Other Terms Option
Other-than-temporary Impairment Analysis Auction Rate Securities Other-than-temporary Impairment Analysis Corporate Debt Securities
Out-license Ono Pharmaceutical Outside Contractor
Overview Ownership Joint Know-how Patent Rights
Ownership Regulatory Approvals Partial Termination Agreement
Participation Awards Participation Progenics8217 Right Refusal
Party Party Agreements
Party Infringement Suit Party Rights Obligations
Patent Markings Patent Rights
Patent Term Extension Paul Jacobson
Paul Maddon Phd Payment Breaches
Payment Performance Awards Payment Stock Appreciation Rights
Payment Stock Unit Awards Pdl Biopharma Inc Formerly Protein Design Labs
Performance Awards Performance Criteria
Person Pharmacovigilance Agreement
Phase Clinical Trial Plan Binding Transferees
Plans Work Pre-approval Audit Non-audit Services Committee
Pre-clinical Tests Press Release
Pricewaterhousecoopers Llp Principal Stockholders Able Exert Significant Influence Over Matters
Prior Agreements Pro 140
Pro 206 Procedure
Product Product Development Programs Inherently Risky
Product Recalls Outside Territory Product Recalls Territory
Profile Progenics
Progenics Announces Management Changes Progenics Announces Positive Top-line Results Pivotal Phase Clinical
Progenics Disclosure Notice Progenics Know-how
Progenics Party Agreement Progenics Party Agreements
Progenics Patent Rights Progenics Patent Rights Joint Japan
Progenics Pharmaceuticals Added Nasdaq Biotechnology Index Progenics Pharmaceuticals Announces Pricing Public Offering Common Stock
Progenics Pharmaceuticals Inc Progenics Pharmaceuticals Inc Condensed Statements Operations Except Loss
Progenics Pharmaceuticals Inc Exact Name Registrant Specified Charter Progenics Pharmaceuticals Inc Public Offering Common Stock
Progenics Pharmaceuticals Inc Restricted Stock Award Agreement Progenics Pharmaceuticals Reports 2005 Results
Progenics Pharmaceuticals Reports End Results Progenics Technology
Pronev Prostate Cancer
Provax Psma
Psma Development Llc Publications
Purpose Pursuant Securities Exchange Act 1934
Quantitative Qualitative Disclosures Market Risk Reason Amendments
Recall Record Keeping
Records Registrational Filing
Regulation Disclosure Regulation Outside
Regulatory Approval Regulatory Authority
Regulatory Marketing Approval Relationships
Relistor Relistor Opioids
Reports Development Representation Legal Counsel
Representations Warranties Each Party Repricing Stock Appreciation Rights Prohibited
Repricing Stock Options Prohibited Requirements
Research Development Expenses Including Clinical Trial Research Grants Contract
Reservation University Rights Responsibilities
Responsibilities Jcc Restricted Cash
Restricted Stock Awards Restricted Stock Awards Rsas
Restrictions Results Operations Financial Condition
Revenue Recognition Revenues
Revised Classification Certain Securities Richard Krawiec Phd
Right Reference Rights Intellectual Property
Rights Obligations Rights Stockholder
Risk Factors Robert Israel
Robert Mckinney Robert Mckinney Cpa
Ronald Prentki Royalty Income
Royalty Period Royalty Statements Payments
Safety Agreement Sales Stock Insiders
San Francisco Tarrytown Schedule 14a
Scope License Scope License University Agreement
Seattle Genetics Seattle Genetics Inc
Sec Filings Other Disclosures Securities Laws
Sen-yo Jisshiken Tohroku Tsujyo Service Process
Setback Clinical Development Programs Adversely Affect Severability
Share Limitation Share-based Payment Arrangements
Shares Subject Plan Sharing Information
Signatures Special Regarding Forward-looking Statements
Specific Performance Specific Responsibilities Jdc
Specific Responsibilities Jsc Specific Terms Option
Stephen Goff Phd Stock Appreciation Rights
Stock Appreciation Rights Sars Stock Awards
Stock Option Exercise Tax Withholding Stock Option Grants 2004
Stock Options Stock Price History Volatility Consider Investment Risky Invest
Stock Unit Awards Stock Units
Stock-based Compensation Stock-based Employee Compensation
Stockholder Proposals Subcutaneous Relistor
Subject Agreements Subject Extensive Regulation Costly Time Consuming Unanticipated Fines
Sublicense Sublicenses
Substantial Portion Funding Comes Federal Government Grants Research Substantial Sales Common Stock Market Price Decline
Substitute Awards Corporate Transactions Successors Assigns
Summary Non-employee Director Compensation Supply
Supply Product Supportive Care
Survival Table Contents
Tandem Stock Option Appreciation Rights Tarrytown
Tarrytown 2008 Tarrytown 2009
Tarrytown Collegeville 2008 Tarrytown Collegeville 2009
Tax Gross-up Tax Withholding
Taxes Withholding Term
Term Amendment Termination Term Stock Options
Termination Termination Cause
Termination Material Definitive Agreement Termination Ono Because Serious Safety Efficacy Commercial Reasons
Termination Ono Cause Termination Ono Serious Safety Efficacy Commercial Reasons
Termination Prior Change-in-control Termination Progenics
Termination Within After Prior Change-in-control Termination Without Cause
Territory Joint Patent Rights Testing Not Yield Successful Results Products Approved
Thomas Boyd Phd Timing Identification Evaluation Process
Title Trademarks
Transfer Documents Data Related Products Japan Transfer Manufacturing Know-how
Transfer Registrational Filings Regulatory Approvals Transfer Restrictions
Unable Negotiate Collaborative Agreements Cash Burn Rate Increase Unable Obtain Sufficient Quantities Raw Bulk Materials Needed
Underpayments Overpayments Unfunded Plan
University Agreement Effect Breach University Chicago
University Compound University Know-how
University Patents Japan University Payments
University Payments Ono Agreement Upfront License Fee Payment
Valid Claim Venue
Vesting Requirements Vesting Stock Options
Vesting Stock Unit Awards Virology
Voting Waiver
Waiver Claims Waiver Jury Trial
Waivers Walter Capone Mba
William Olson Phd Witness Whereof
Working Groups Wyeth
Wyeth Agreement Wyeth Collaboration
Wyeth Collaboration Joint Know-how Wyeth Collaboration Joint Patent Rights
Wyeth Collaboration Know-how Wyeth Collaboration Patent Rights
Wyeth Disclosure Notice Wyeth Pharmaceuticals
Wyeth Technology 8220 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki